## a.) Amendment to the Claims:

1. (Original) An adenosine  $A_{2A}$  receptor antagonist comprising, as the active ingredient, a thiazole derivative represented by a general formula (I):

$$R^{2}-(CH_{2})_{n}$$

$$R^{2}$$

$$(I)$$

{wherein;

n represents an integer of from 0 to 3;

R<sup>1</sup> represents substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl,

a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group;

R<sup>2</sup> represents a halogen,

substituted or unsubstituted lower alkyl,
substituted or unsubstituted lower alkenyl,
substituted or unsubstituted lower alkynyl,
substituted or unsubstituted cycloalkyl,

substituted or unsubstituted aralkyl,

a substituted or unsubstituted alicyclic heterocyclic group,

a substituted or unsubstituted aromatic heterocyclic group,

substituted or unsubstituted alicyclic heterocyclic-alkyl,

substituted or unsubstituted aromatic heterocyclic-alkyl,

-NR<sup>5</sup>R<sup>6</sup> (wherein

R<sup>5</sup> and R<sup>6</sup> may be the same or different, and each represents

a hydrogen atom,

substituted or unsubstituted lower alkyl,

substituted or unsubstituted lower alkenyl,

substituted or unsubstituted lower alkynyl,

substituted or unsubstituted lower alkanoyl,

substituted or unsubstituted cycloalkyl,

substituted or unsubstituted aryl,

substituted or unsubstituted aralkyl,

a substituted or unsubstituted alicyclic heterocyclic group,
a substituted or unsubstituted aromatic heterocyclic group,
substituted or unsubstituted alicyclic heterocyclic-alkyl, or
substituted or unsubstituted aromatic heterocyclic-alkyl),
-OR<sup>7</sup> (wherein

R<sup>7</sup> represents a hydrogen atom,

substituted or unsubstituted lower alkanoyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl,
a substituted or unsubstituted alicyclic heterocyclic group,
a substituted or unsubstituted aromatic heterocyclic group,
substituted or unsubstituted alicyclic heterocyclic-alkyl, or
substituted or unsubstituted aromatic heterocyclic-alkyl), or
-COR<sup>8</sup> [wherein

R<sup>8</sup> represents a hydrogen atom,

substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted alicyclic heterocyclic-alkyl, substituted or unsubstituted aromatic heterocyclic-alkyl, -NR<sup>9</sup>R<sup>10</sup> (wherein

 $R^9$  and  $R^{10}$  may be the same or different, and each represent

a hydrogen atom,

substituted or unsubstituted lower alkyl,

substituted or unsubstituted lower alkenyl,

substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted alicyclic heterocyclic-alkyl, or substituted or unsubstituted aromatic heterocyclic-alkyl), or -OR<sup>11</sup> (wherein

R<sup>11</sup> represents a hydrogen atom,

substituted or unsubstituted lower alkyl,
substituted or unsubstituted lower alkenyl,
substituted or unsubstituted lower alkynyl,
substituted or unsubstituted cycloalkyl,

substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted alicyclic heterocyclic-alkyl, or substituted or unsubstituted aromatic heterocyclic-alkyl)]; and R<sup>3</sup> and R<sup>4</sup> may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted alicyclic heterocyclic-alkyl, substituted or unsubstituted aromatic heterocyclic-alkyl, -COR<sup>12</sup> [wherein

R<sup>12</sup> represents a hydrogen atom,

substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted alicyclic heterocyclic-alkyl, substituted or unsubstituted aromatic heterocyclic-alkyl, -NR<sup>13</sup>R<sup>14</sup> (wherein R<sup>13</sup> and R<sup>14</sup> may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl,

substituted or unsubstituted lower alkynyl,

substituted or unsubstituted lower alkanoyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl,
a substituted or unsubstituted alicyclic heterocyclic group,
a substituted or unsubstituted aromatic heterocyclic group,
substituted or unsubstituted alicyclic heterocyclic-alkyl, or
substituted or unsubstituted aromatic heterocyclic-alkyl), or
-OR<sup>15</sup> (wherein

R<sup>15</sup> represents a hydrogen atom,

substituted or unsubstituted lower alkyl,
substituted or unsubstituted lower alkenyl,
substituted or unsubstituted lower alkynyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl,

substituted or unsubstituted aralkyl,

a substituted or unsubstituted alicyclic heterocyclic group,

a substituted or unsubstituted aromatic heterocyclic group,

substituted or unsubstituted alicyclic heterocyclic-alkyl, or

substituted or unsubstituted aromatic heterocyclic-alkyl)];

provided that,

when R<sup>1</sup> is substituted or unsubstituted phenyl and n is 0,

then R<sup>2</sup> is not substituted or unsubstituted 6-oxo-1,6-dihydropyridazin-3-

or a pharmaceutically acceptable salt thereof.

yl},

- 2. (Original) The adenosine  $A_{2A}$  receptor antagonist according to claim 1, wherein  $R^1$  is substituted or unsubstituted aryl, or a substituted or unsubstituted aromatic heterocyclic group.
- 3. (Original) The adenosine  $A_{2A}$  receptor antagonist according to claim 1 or 2, wherein n is 0.

- 4. (Currently Amended) The adenosine  $A_{2A}$  receptor antagonist according to any one of claims 1 to 3 claim 1 or 2, wherein  $R^2$  is substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted or unsubstituted or unsubstituted aromatic heterocyclic-alkyl, substituted or unsubstituted aromatic heterocyclic-alkyl, or -COR<sup>8</sup> (wherein R<sup>8</sup> has the same meaning as defined above).
- 5. (Currently Amended) The adenosine  $A_{2A}$  receptor antagonist according to any one of claims 1 to 3 claim 1 or 2, wherein  $R^2$  is substituted or unsubstituted aryl.
- 6. (Currently Amended) The adenosine A<sub>2A</sub> receptor antagonist according to any one of claims 1 to 3 claim 1 or 2, wherein R<sup>2</sup> is a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group.
- 7. (Currently Amended) The adenosine A<sub>2A</sub> receptor antagonist according to any one of claims 1 to 3 claim 1 or 2, wherein R<sup>2</sup> is -COR<sup>8</sup> (wherein R<sup>8</sup> has the same meaning as defined above).
- 8. (Currently Amended) The adenosine  $A_{2A}$  receptor antagonist according to any one of claims 1 to 4 and 7 claim 7, wherein  $R^8$  is a hydrogen atom, substituted or

unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted or unsubstituted or unsubstituted aromatic heterocyclic-alkyl, or substituted or unsubstituted aromatic heterocyclic-alkyl.

- 9. (Currently Amended) The adenosine A<sub>2A</sub> receptor antagonist according to any one of claims 1 to 4 and 7 claim 7, wherein R<sup>8</sup> is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group.
- 10. (Currently Amended) The adenosine  $A_{2A}$  receptor antagonist according to any one of claims 1 to 4 and 7 claim 7, wherein  $R^8$  is substituted or unsubstituted arryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group.
- 11. (Currently Amended) The adenosine  $A_{2A}$  receptor antagonist according to any one of claims 1 to 10 claim 2, wherein  $R^3$  is a hydrogen atom.

- 12. (Currently Amended) The adenosine A<sub>2A</sub> receptor antagonist according to any one of claims 1 to 10 claim 2, wherein R<sup>3</sup> is lower alkyl or aralkyl.
- 13. (Currently Amended) The adenosine  $A_{2A}$  receptor antagonist according to claim 11 or 12, wherein  $R^4$  is -COR<sup>12</sup> (wherein  $R^{12}$ -has the same meaning as defined above).
- 14. (Original) The adenosine A<sub>2A</sub> receptor antagonist according to claim 11 or 12, wherein R<sup>4</sup> is -COR<sup>12a</sup> (wherein R<sup>12a</sup> is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted alicyclic heterocyclic-alkyl, or substituted or unsubstituted aromatic heterocyclic-alkyl).
- 15. (Currently Amended) The adenosine  $A_{2A}$  receptor antagonist according to any one of claims 1 to 10 claim 6, wherein  $R^3$  and  $R^4$  may be the same or different, and each represents -COR<sup>12</sup> (wherein  $R^{12}$  has the same meaning as defined above).

- 16. (Original) The adenosine  $A_{2A}$  receptor antagonist according to claim 1, wherein n is 0;  $R^1$  is a substituted or unsubstituted 5-membered aromatic heterocyclic group containing at least one oxygen atom; and  $R^2$  is -COR<sup>8a</sup> (wherein R<sup>8a</sup> represents a substituted or unsubstituted alicyclic heterocyclic group).
- 17. (Original) The adenosine  $A_{2A}$  receptor antagonist according to claim 16, wherein  $R^1$  is substituted or unsubstituted furyl.
- 18. (Original) The adenosine  $A_{2A}$  receptor antagonist according to claim 16 or 17, wherein  $R^{8a}$  is a substituted or unsubstituted alicyclic heterocyclic group containing at least one oxygen atom.
- 19. (Currently Amended) The adenosine A<sub>2A</sub> receptor antagonist according to any one of claims 1 to 10 and 16 to 18 claim 18, wherein R<sup>3</sup> is a hydrogen atom; and R<sup>4</sup> is substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted aromatic heterocyclic-alkyl.
- 20. (Currently Amended) The adenosine  $A_{2A}$  receptor antagonist according to any one of claims 1 to 10 and 16 to 18 claim 18, wherein  $R^3$  is a hydrogen atom,; and  $R^4$  is lower alkyl, aralkyl, or aromatic heterocyclic-alkyl.

- 21. (Currently Amended) The adenosine  $A_{2A}$  receptor antagonist according to any one of claims 1 to 10 and 16 to 18 claim 18, wherein  $R^3$  and  $R^4$  may be the same or different, and each represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted aromatic heterocyclic-alkyl.
- 22. (Currently Amended) An agent for treating and/or preventing diseases associated with adenosine A<sub>2A</sub>-receptor A pharmaceutical agent comprising, as the active ingredient, a thiazole derivative according to any one of claims 1 to 21 claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

Claim 23 (Cancelled).

24. A thiazole derivative represented by a formula (IA):

$$R^{2A} - (CH_2)_n \qquad S \qquad R^{3A}$$

$$R^{2A} - (CH_2)_n \qquad (IA)$$

[wherein

R<sup>1A</sup> represents a substituted or unsubstituted 5-membered aromatic heterocyclic group containing at least one oxygen atom (excluding a group selected from 5-phosphonofuran-2-yl and 5-nitrofuran-2-yl);

n represents an integer of from 0 to 3;

R<sup>12</sup> and n have the same meanings as defined above, respectively; represents a hydrogen atom,

substituted or unsubstituted lower alkynyl,
substituted or unsubstituted lower alkynyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl,
a substituted or unsubstituted alicyclic heterocyclic group,
substituted or unsubstituted alicyclic heterocyclic group,
substituted or unsubstituted alicyclic heterocyclic-alkyl,
substituted or unsubstituted aromatic heterocyclic-alkyl,

## -NR<sup>13</sup>R<sup>14</sup> (wherein

R<sup>13</sup> and R<sup>14</sup> may be the same or different, and each represents

a hydrogen atom,

substituted or unsubstituted lower alkyl,

substituted or unsubstituted lower alkenyl,

substituted or unsubstituted lower alkynyl,

substituted or unsubstituted lower alkanoyl,

substituted or unsubstituted lower alkoxy,

substituted or unsubstituted cycloalkyl,

substituted or unsubstituted aryl,

substituted or unsubstituted aralkyl,

a substituted or unsubstituted alicyclic heterocyclic group,

a substituted or unsubstituted aromatic heterocyclic group,

substituted or unsubstituted alicyclic heterocyclic-alkyl, or

substituted or unsubstituted aromatic heterocyclic-alkyl), or

-OR<sup>15</sup> (wherein

## R<sup>15</sup> represents a hydrogen atom,

substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted alicyclic heterocyclic-alkyl, or substituted or unsubstituted aromatic heterocyclic-alkyl)]; n represents an integer of from 0 to 3;

R<sup>3A</sup> represents a hydrogen atom;

substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl,

substituted or unsubstituted aralkyl, substituted or unsubstituted alicyclic heterocyclic-alkyl, substituted or unsubstituted aromatic heterocyclic-alkyl, or -COR<sup>12A</sup> (wherein R<sup>12A</sup> have the same meaning as that of R<sup>12</sup>); and R<sup>2A</sup> represents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group (excluding 2furyl), substituted or unsubstituted alicyclic heterocyclic-alkyl, substituted or unsubstituted aromatic heterocyclic-alkyl, -NR<sup>5</sup>R<sup>6</sup> (wherein R<sup>5</sup> and R<sup>6</sup> have the same meanings as defined above,

respectively) may be the same or different, and each represents

a hydrogen atom,

substituted or unsubstituted lower alkyl,

substituted or unsubstituted lower alkenyl,

substituted or unsubstituted lower alkynyl,

substituted or unsubstituted lower alkanoyl,

substituted or unsubstituted cycloalkyl,

substituted or unsubstituted aryl,

substituted or unsubstituted aralkyl,

a substituted or unsubstituted alicyclic heterocyclic group,
a substituted or unsubstituted aromatic heterocyclic group,
substituted or unsubstituted alicyclic heterocyclic-alkyl, or
substituted or unsubstituted aromatic heterocyclic-alkyl),

-OR<sup>7</sup> (wherein

R<sup>7</sup> represents a hydrogen atom,

substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkanoyl,

substituted or unsubstituted aryl,

substituted or unsubstituted aralkyl,

a substituted or unsubstituted alicyclic heterocyclic group,

a substituted or unsubstituted aromatic heterocyclic group,

substituted or unsubstituted alicyclic heterocyclic-alkyl, or

-OR<sup>7</sup> (wherein R<sup>7</sup> has the same meaning as defined above), or

substituted or unsubstituted aromatic heterocyclic-alkyl,

-COR<sup>8</sup> (wherein R<sup>8</sup> has the same meaning as defined above) represents a hydrogen atom,

substituted or unsubstituted lower alkyl,

substituted or unsubstituted lower alkenyl,

substituted or unsubstituted lower alkynyl,

substituted or unsubstituted cycloalkyl,

substituted or unsubstituted aryl,

substituted or unsubstituted aralkyl,

a substituted or unsubstituted alicyclic heterocyclic group,

a substituted or unsubstituted aromatic heterocyclic group,
substituted or unsubstituted alicyclic heterocyclic-alkyl,
substituted or unsubstituted aromatic heterocyclic-alkyl,
-NR<sup>9</sup>R<sup>10</sup> (wherein

R<sup>9</sup> and R<sup>10</sup> may be the same or different, and each represent

a hydrogen atom,

substituted or unsubstituted lower alkyl,

substituted or unsubstituted lower alkenyl,

substituted or unsubstituted lower alkynyl,

substituted or unsubstituted lower alkanoyl,

substituted or unsubstituted lower alkoxy,

substituted or unsubstituted cycloalkyl,

substituted or unsubstituted aryl,

substituted or unsubstituted aralkyl,

a substituted or unsubstituted alicyclic heterocyclic group,

a substituted or unsubstituted aromatic heterocyclic group,

substituted or unsubstituted alicyclic heterocyclic-alkyl, or substituted or unsubstituted aromatic heterocyclic-alkyl), or -OR<sup>11</sup> (wherein

R<sup>11</sup> represents a hydrogen atom,

substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted alicyclic heterocyclic-alkyl, or substituted or unsubstituted aromatic heterocyclic-alkyl), or a pharmaceutically acceptable salt thereof.

- 25. (Original) The thiazole derivative according to claim 24, wherein R<sup>1A</sup> is substituted or unsubstituted furyl, or a pharmaceutically acceptable salt thereof.
- 26. (Original) The thiazole derivative according to claim 24 or 25, wherein n is 0, or a pharmaceutically acceptable salt thereof.
- 27. (Currently Amended) The thiazole derivative according to any one of elaims 24 to 26 claim 24 or 25, wherein R<sup>2A</sup> is substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted alicyclic heterocyclic-alkyl, substituted or unsubstituted aromatic heterocyclic-alkyl, or -COR<sup>8</sup> (wherein R<sup>8</sup> has the same meaning as defined above), or a pharmaceutically acceptable salt thereof.
- 28. (Currently Amended) The thiazole derivative according to any one of elaims 24 to 26 claim 24 or 25, wherein R<sup>2A</sup> is substituted or unsubstituted aryl, or a pharmaceutically acceptable salt thereof.
- 29. (Currently Amended) The thiazole derivative according to any one of claims 24 to 26 claim 24 or 25, wherein R<sup>2A</sup> is a substituted or unsubstituted alicyclic

heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group, or a pharmaceutically acceptable salt thereof.

- 30. (Currently Amended) The thiazole derivative according to any one of elaims 24 to 26 claim 24 or 25, wherein R<sup>2A</sup> is -COR<sup>8</sup> (wherein R<sup>8</sup> has the same meaning as defined above), or a pharmaceutically acceptable salt thereof.
- 31. (Original) The thiazole derivative according to claim 30, wherein R<sup>8</sup> is a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted alicyclic heterocyclic-alkyl, or substituted or unsubstituted aromatic heterocyclic-alkyl, or a pharmaceutically acceptable salt thereof.
- 32. (Original) The thiazole derivative according to claim 30, wherein R<sup>8</sup> is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group, or a pharmaceutically acceptable salt thereof.

- 33. (Original) The thiazole derivative according to claim 30, wherein R<sup>8</sup> is substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group, or a pharmaceutically acceptable salt thereof.
- 34. (Currently Amended) The thiazole derivative according to any one of elaims 24 to 33 claim 27, wherein R<sup>3A</sup> is a hydrogen atom, or a pharmaceutically acceptable salt thereof.
- 35. (Currently Amended) The thiazole derivative according to any one of elaims 24 to 33 claim 27, wherein R<sup>3A</sup> is lower alkyl or aralkyl, or a pharmaceutically acceptable salt thereof.
- 36. (Currently Amended) The thiazole derivative according to any one of elaims 24 to 33 claim 27, wherein R<sup>3A</sup> is -COR<sup>12A</sup> (wherein R<sup>12A</sup> has the same meaning as defined above), or a pharmaceutically acceptable salt thereof.
- 37. (Original) The thiazole derivative according to claim 36, wherein R<sup>12A</sup> is substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy,

substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted alicyclic heterocyclic-alkyl, or substituted or unsubstituted aromatic heterocyclic-alkyl, or a pharmaceutically acceptable salt thereof.

- 38. (Currently Amended) The thiazole derivative according to any one of elaims 24 to 37 claim 27, wherein R<sup>12</sup> is substituted or unsubstituted lower alkyl, substituted or unsubstituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, a substituted or unsubstituted ariselylic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted alicyclic heterocyclic-alkyl, or substituted or unsubstituted aromatic heterocyclic-alkyl, or a pharmaceutically acceptable salt thereof.
- 39. (Currently Amended) A thiazole derivatives represented by a formula (IB):

$$R^{8B}$$
 $(CH_2)_n$ 
 $(CH_2)_n$ 
 $(CH_2)_n$ 
 $(CH_2)_n$ 
 $(CH_2)_n$ 
 $(CH_2)_n$ 
 $(CH_2)_n$ 

(wherein

n and R<sup>1A</sup> have the same meanings as defined above, respectively represents an integer of from 0 to 3;

R<sup>1A</sup> represents a substituted or unsubstituted 5-membered aromatic heterocyclic group containing at least one oxygen atom (excluding a group selected from 5-phosphonofuran-2-yl and 5-nitrofuran-2-yl);

R<sup>3B</sup> represents a hydrogen atom,

substituted or unsubstituted lower alkyl,

substituted or unsubstituted lower alkenyl,

substituted or unsubstituted lower alkynyl,

substituted or unsubstituted aralkyl,

substituted or unsubstituted alicyclic heterocyclic-alkyl, or

substituted or unsubstituted aromatic heterocyclic-alkyl;

 $R^{4B}$  represents substituted or unsubstituted lower alkyl,

substituted or unsubstituted lower alkenyl,

substituted or unsubstituted lower alkynyl,

substituted or unsubstituted aralkyl,

substituted or unsubstituted alicyclic heterocyclic-alkyl, or substituted or unsubstituted aromatic heterocyclic-alkyl; and

R<sup>8B</sup> represents a hydrogen atom,

substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, substituted or unsubstituted alicyclic heterocyclic-alkyl, or substituted or unsubstituted aromatic heterocyclic-alkyl), or a pharmaceutically acceptable salt thereof.

40. (Original) The thiazole derivative according to claim 39, wherein R<sup>1A</sup> is substituted or unsubstituted furyl, or a pharmaceutically acceptable salt thereof.

- 41. (Original) The thiazole derivative according to claim 39 or 40, wherein n is 0, or a pharmaceutically acceptable salt thereof.
- 42. (Currently Amended) The thiazole derivative according to any one of elaims 39 to 41 claims 39 or 40, wherein R<sup>8B</sup> is a substituted or unsubstituted alicyclic heterocyclic group containing at least one oxygen atom, or a pharmaceutically acceptable salt thereof.
- 43. (Currently Amended) The thiazole derivative according to any one of elaims 39 to 42 Claims 39 or 40, wherein R<sup>3B</sup> is a hydrogen atom, or a pharmaceutically acceptable salt thereof.

Claims 44-47 (Cancelled).

48. (Currently Amended) An agent for treating and/or preventing The method according to claim 50, wherein the disease is a central nervous system disease diseases comprising, as the active ingredient, a thiazole derivative according to any one of claims 24 to 44, or a pharmaceutically acceptable salt thereof.

- 49. (Currently Amended) An agent for treating and/or preventing The method according to claim 50, wherein the disease is Parkinson's disease comprising, as the active ingredient, a thiazole derivative according to any one of claims 24 to 44, or a pharmaceutically acceptable salt thereof.
- 50. (Currently Amended) A method for treating and/or preventing diseases associated with adenosine A<sub>2A</sub> receptor and/or preventing symptoms associated with those diseases, which comprises administering an effective amount of a thiazole derivative represented by a general formula (I):

$$\begin{array}{c|c}
R^1 & R^3 \\
\hline
R^2 - (CH_2)_n & R^4 \\
\hline
- (H) - \\
\end{array}$$

(wherein n, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> have the same meanings as defined above, respectively) according to claims 1 or 2, or a pharmaceutically acceptable salt thereof to a patient in need thereof.